British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA Study)

Monitoring the long-term safety of biologic, biosimilar, and other new targeted therapies in the UK.
Over 30,000 patients registered in the study since 2001.

NOW ACCEPTING NEW REGISTRATIONS AND FOLLOW-UP DATA ONLINE VIA THE NEW WEB PORTAL!

To sign up please visit https://bsrbr.org/database/

Eligibility for registration

- Diagnosis of Rheumatoid Arthritis
- Aged 16 Years or over
- Starting eligible biologic treatment

ANTI-TNF
- HUMIRA (adalimumab originator)*
- ENBREL (etanercept originator)*
- REMICADE (infliximab originator)*

*patients must be biologic, biosimilar & targeted therapy naive to be eligible

BIOSIMILARS
- HULIO (adalimumab)
- AMGEVITA (adalimumab)
- HYRIMOZ (adalimumab)
- IMRALDI (adalimumab)
- RIXATHON (rituximab)
- IDACIO (adalimumab)
- RUXIENCE (rituximab)
- ERELZI (etanercept)
- BENEPALI (etanercept)
- INFLECTRA (infliximab)
- REMSIMA IV (infliximab)
- REMSIMA SC (infliximab)
- FLIXABI (infliximab)

OTHER TARGETED THERAPIES
- OLUIMIANT (baricitinib)
- ROACTEMRA (tocilizumab)
- CIMZIA (certolizumab)
- KEVZARA (sarilumab)
- XELJANZ (tocilizumab)
- RINVOQ (upadacitinib)
- JYSELECA (filgotinib)

Registration within 6 months of the therapy start date*

*For patients already registered who are starting a new therapy, cohort switch request needs to be made within 24 months of therapy start.

Please contact the BSRBR-RA team with any questions
0161 275 1652 / 7390 biologics.register@manchester.ac.uk

Recruiting to BSRBR-RA

V15: 25/05/2021